Every 8-K that Moleculin Biotech, Inc. (MBRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MBRX filings page.
Moleculin Biotech, Inc. filed a Current Report on Form 8-K disclosing that on September 8, 2025 the company posted and is using an Investor Presentation dated September 2025 as its corporate presentation and furnished that presentation as Exhibit 99.1. The filing states the furnished presentation is not being "filed" under the Exchange Act and will not be incorporated by reference into future filings unless expressly identified. The report identifies the registrant, principal executive office address in Houston, Texas, trading symbol MBRX on NASDAQ, and includes the Exhibit list and Inline XBRL cover page reference.
Moleculin Biotech announced the start of EU enrollment in its pivotal Phase 2B/3 trial of Annamycin combined with cytarabine (AnnAraC) for adults with relapsed or refractory acute myeloid leukemia (R/R AML). The company reported that the first two subjects in the European Union have been enrolled and one subject has been treated, marking initiation of EU participation in a multi-center, randomized, double-blind, placebo-controlled, adaptive-design study.
The press release is attached as an exhibit to the company's report and is being furnished rather than filed. The disclosure focuses on clinical development progress—specifically geographic expansion of patient enrollment in a late-stage trial evaluating Annamycin plus Ara-C for R/R AML.
Moleculin Biotech, Inc. reported two corporate actions in this Current Report. Stockholders approved and the company filed a Certificate Amendment to increase authorized common shares from 100,000,000 to 500,000,000, which became effective upon filing with the Delaware Secretary of State on August 21, 2025. The company also furnished a press release dated August 27, 2025 announcing completion of its Phase 1B/2 (MB-106) clinical trial evaluating Annamycin combined with Cytarabine (referred to as AnnAraC) for treatment of subjects with acute myeloid leukemia (AML). The Certificate Amendment and the press release are attached as exhibits.
Moleculin Biotech, Inc. (MBRX) filed a Form 8-K reporting a Regulation FD disclosure that the company posted an investor presentation dated August 2025 to its website and furnished the presentation as Exhibit 99.1. The filing clarifies the furnished exhibit is not being "filed" under the Securities Exchange Act and will not be incorporated by reference into other SEC filings unless expressly stated. No financial results, transactions, or forward-looking guidance are included in this report.
Moleculin Biotech, Inc. reported results from its annual meeting held August 18, 2025. Stockholders elected six directors to serve until the next annual meeting and approved several governance and compensation measures. Shareholders approved an amendment to the 2024 Equity Incentive Plan, a non-binding advisory vote on executive compensation, the issuance of up to 6,542,058 shares upon exercise of certain warrants issued February 26, 2025, an amendment increasing authorized common shares from 100,000,000 to 500,000,000, and an amendment granting the board authority to effect a reverse stock split. The proposal to eliminate supermajority voting requirements was not approved.
Vote totals are reported for each matter (for example, Proposal to increase authorized shares: 4,320,277 for, 1,697,864 against, 22,971 abstentions). The report was signed by the Chief Financial Officer.
Moleculin Biotech, Inc. disclosed that it issued a press release reporting its financial results for the quarter ended June 30, 2025 and recent operational highlights. The press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference into the filing.
The 8-K filing itself does not present numerical revenue, profit, cash flow or balance sheet figures; investors must consult the attached press release for detailed results and metrics. The company’s common stock trades under the ticker MBRX on The NASDAQ Stock Market. The filing also lists an Inline XBRL cover page as Exhibit 104, indicating machine-readable cover data is included with the submission.
Item 7.01 – Regulation FD: On 30 Jul 2025 Moleculin Biotech, Inc. (NASDAQ: MBRX) furnished an 8-K announcing it has received a Notice of Intent to Grant for European patent application “Preparation of Pre-liposomal Annamycin Lyophilizate.”
The disclosure, provided via attached Exhibit 99.1, indicates the patent is expected to cover the Company’s Annamycin formulation in Europe once formally issued. No financial statements, earnings data or other operational metrics are included. The information is expressly furnished, not filed, and therefore will not be incorporated into other Exchange Act or Securities Act reports unless later referenced. Exhibit 104 supplies the Inline XBRL cover page.
Moleculin Biotech (MBRX) has announced a significant public offering totaling $5.9 million in gross proceeds, with potential for an additional $17.8 million if all warrants are exercised. The offering, which closed on June 23, 2025, includes:
- 9,972,026 shares of common stock
- 6,107,974 pre-funded warrants at $0.001 exercise price
- 48,240,000 Series E warrants at $0.37 initial exercise price
Notable aspects include insider participation, with CEO Walter Klemp and CFO Jonathan Foster purchasing 1,027,026 shares and 3,081,078 warrants. Roth Capital Partners served as placement agent, receiving a 7% fee. The proceeds will fund clinical development of Annamycin and two other drug portfolios, preclinical studies, and working capital.
The offering includes significant stockholder approval requirements and anti-dilution provisions, with warrant exercise prices subject to potential downward adjustments (floor price $0.12). The company has agreed to a 60-day restriction on new share issuances following stockholder approvals.